Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure ≥25 mm Hg
at rest, measured during right heart catheterization. There is still insufficient evidence to add …

Background Riociguat, a member of a new class of compounds (soluble guanylate cyclase
stimulators), has been shown in previous clinical studies to be beneficial in the treatment of …

Our understanding of, and approach to, pulmonary arterial hypertension has undergone a
paradigm shift in the past decade. Once a condition thought to be dominated by increased …

Most patients with rare diseases do not receive a molecular diagnosis and the aetiological
variants and causative genes for more than half such disorders remain to be discovered 1 . …

Pulmonary arterial hypertension (PAH) is a syndrome in which pulmonary arterial obstruction
increases pulmonary vascular resistance, which leads to right ventricular (RV) failure and a …

Objective To investigate the risk of incident myocardial infarction, congestive heart failure,
and all cause mortality associated with prescription of oral antidiabetes drugs. Design …

Rationale: Phosphodiesterase type 5 (PDE5) inhibition has been proposed for the treatment
for pulmonary arterial hypertension (PAH). Objective: This study compared adding sildenafil…

Rationale: Phosphodiesterase Type 5 (PDE5) inhibition represents a novel strategy for the
treatment of pulmonary hypertension. Objectives: Our aim was to establish the distribution of …

The discovery in the early 1980s of atrial natriuretic peptide, a circulating peptide with
natriuretic/diuretic and vasorelaxant properties was greeted with excitement since the existence of …

Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious
variation within components of the transforming growth factor-β pathway, particularly the …